Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation
© 2023. The Author(s)..
Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 13. Jan., Seite 199 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 17.01.2023 Date Revised 07.03.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-35928-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351503226 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351503226 | ||
| 003 | DE-627 | ||
| 005 | 20231226051523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-35928-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351503226 | ||
| 035 | |a (NLM)36639383 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Souza, Thiago Moreno L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2023 | ||
| 500 | |a Date Revised 07.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endowed with both antiviral and anti-inflammatory activity are highly desirable. We identified here that kinetin (MB-905) inhibits the in vitro replication of SARS-CoV-2 in human hepatic and pulmonary cell lines. On infected monocytes, MB-905 reduced virus replication, IL-6 and TNFα levels. MB-905 is converted into its triphosphate nucleotide to inhibit viral RNA synthesis and induce error-prone virus replication. Coinhibition of SARS-CoV-2 exonuclease, a proofreading enzyme that corrects erroneously incorporated nucleotides during viral RNA replication, potentiated the inhibitory effect of MB-905. MB-905 shows good oral absorption, its metabolites are stable, achieving long-lasting plasma and lung concentrations, and this drug is not mutagenic nor cardiotoxic in acute and chronic treatments. SARS-CoV-2-infected hACE-mice and hamsters treated with MB-905 show decreased viral replication, lung necrosis, hemorrhage and inflammation. Because kinetin is clinically investigated for a rare genetic disease at regimens beyond the predicted concentrations of antiviral/anti-inflammatory inhibition, our investigation suggests the opportunity for the rapid clinical development of a new antiviral substance for the treatment of COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Kinetin |2 NLM | |
| 650 | 7 | |a P39Y9652YJ |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 700 | 1 | |a Pinho, Vagner D |e verfasserin |4 aut | |
| 700 | 1 | |a Setim, Cristina F |e verfasserin |4 aut | |
| 700 | 1 | |a Sacramento, Carolina Q |e verfasserin |4 aut | |
| 700 | 1 | |a Marcon, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a Fintelman-Rodrigues, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Chaves, Otavio A |e verfasserin |4 aut | |
| 700 | 1 | |a Heller, Melina |e verfasserin |4 aut | |
| 700 | 1 | |a Temerozo, Jairo R |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, André C |e verfasserin |4 aut | |
| 700 | 1 | |a Mattos, Mayara |e verfasserin |4 aut | |
| 700 | 1 | |a Momo, Patrícia B |e verfasserin |4 aut | |
| 700 | 1 | |a Dias, Suelen S G |e verfasserin |4 aut | |
| 700 | 1 | |a Gesto, João S M |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira-Dutra, Filipe |e verfasserin |4 aut | |
| 700 | 1 | |a Viola, João P B |e verfasserin |4 aut | |
| 700 | 1 | |a Queiroz-Junior, Celso Martins |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Lays Cordeiro |e verfasserin |4 aut | |
| 700 | 1 | |a Chaves, Ian Meira |e verfasserin |4 aut | |
| 700 | 1 | |a Guimarães, Pedro Pires Goulart |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Vivian Vasconcelos |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira, Mauro Martins |e verfasserin |4 aut | |
| 700 | 1 | |a Bou-Habib, Dumith Chequer |e verfasserin |4 aut | |
| 700 | 1 | |a Bozza, Patrícia T |e verfasserin |4 aut | |
| 700 | 1 | |a Aguillón, Anderson R |e verfasserin |4 aut | |
| 700 | 1 | |a Siqueira-Junior, Jarbas |e verfasserin |4 aut | |
| 700 | 1 | |a Macedo-Junior, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Edineia L |e verfasserin |4 aut | |
| 700 | 1 | |a Fadanni, Guilherme P |e verfasserin |4 aut | |
| 700 | 1 | |a Tolouei, Sara E L |e verfasserin |4 aut | |
| 700 | 1 | |a Potrich, Francine B |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Adara A |e verfasserin |4 aut | |
| 700 | 1 | |a Marques, Naiani F |e verfasserin |4 aut | |
| 700 | 1 | |a Calixto, João B |e verfasserin |4 aut | |
| 700 | 1 | |a Rabi, Jaime A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 13. Jan., Seite 199 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:13 |g month:01 |g pages:199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-35928-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 13 |c 01 |h 199 | ||